SKYE (STOCKS)
Skye Bioscience, Inc. Common Stock
$0.749400
+0.029400 (+4.08%)
Prev close: $0.720000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Punit S. Dhillon
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $24.12M
- Employees
- 16
- P/E (TTM)
- -0.51
- P/B (TTM)
- 1.20
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $2.24M |
| Operating Expenses | $58.16M |
| Operating Income/Loss | -$58.16M |
| Income/Loss From Continuing Operations After Tax | -$55.92M |
| Income/Loss From Continuing Operations Before Tax | -$55.92M |
| Income Tax Expense/Benefit | $5.40K |
| Income Tax Expense/Benefit, Current | $5.40K |
| Interest Expense, Operating | $0.00 |
| Net Income/Loss | -$55.92M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$55.92M |
| Net Income/Loss Available To Common Stockholders, Basic | -$55.92M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.41 |
| Diluted Earnings Per Share | -$1.41 |
| Basic Average Shares | 39,662,664 |
| Diluted Average Shares | 39,662,664 |
| Assets | $28.31M |
| Current Assets | $27.09M |
| Cash | $25.74M |
| Prepaid Expenses | $504.89K |
| Other Current Assets | $852.04K |
| Noncurrent Assets | $1.22M |
| Fixed Assets | $898.93K |
| Other Non-current Assets | $320.56K |
| Liabilities | $8.29M |
| Current Liabilities | $8.21M |
| Accounts Payable | $2.03M |
| Wages | $1.27M |
| Other Current Liabilities | $4.90M |
| Noncurrent Liabilities | $84.00K |
| Equity | $20.02M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $20.02M |
| Liabilities And Equity | $28.31M |
| Net Cash Flow From Operating Activities | -$43.06M |
| Net Cash Flow From Operating Activities, Continuing | -$43.06M |
| Net Cash Flow From Investing Activities | -$19.50M |
| Net Cash Flow From Investing Activities, Continuing | -$19.50M |
| Net Cash Flow From Financing Activities | $29.57K |
| Net Cash Flow From Financing Activities, Continuing | $29.57K |
| Net Cash Flow | -$62.53M |
| Net Cash Flow, Continuing | -$62.53M |
| Comprehensive Income/Loss | -$55.92M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$55.92M |
| Other Comprehensive Income/Loss | $0.00 |